GlobeNewswire by notified

DNAtix Successfully Transferred Craig Venter's Y Chromosome Using IBM Blockchain

Share

Genetic Revolution Breakthrough Will Help Advance Preventive and Personalized Medicine

TEL-AVIV, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- Digital DNAtix Ltd., the genetics blockchain company, announced the first successful transfer of a complete chromosome using blockchain technology.  With the help of IBM's Hyperledger fabric, DNAtix transferred the chromosome of genome pioneer Craig Venter, an accomplishment which further propels humanity into new discoveries in the cutting-edge frontier of genetics research and solutions.

Craig Venter, genome pioneer and world-renowned geneticist, published his full genomic data in PLOS magazine in September 2007. (1)  Venter's team used his DNA to generate an assembled diploid human genomic DNA sequencefrom both chromosomes. In the article, the authors compared Venter's sequence to reference human genome sequences to enable the study of human DNA.

"Transferring the full sequence of a virus was a challenging project but it is 'a piece of cake' compared to transferring the sequence of a full chromosome," says Ofer A. Lidsky, CEO & CTO and Co-founder of DNAtix. "We are working with genetic data and size does matter when it comes to blockchain."

IBM HYPERLEDGER
To deal with the size limitation of the current blockchain technologies, DNAtix's development team sliced Craig Venter's published DNA sequence into 19 fragments.  DNAtix used the Hyperledger Composer tool with JavaScript to transfer the 19 transactions containing the genetic code as metadata. DNAtix will release a whitepaper with an in-depth description of what the development team accomplished.  

"Our next goal is to transfer a full human genome sequence over the blockchain to enable genetic information to be shared in an anonymous and secure way," said Dr. Tal Sines, DNAtix Chief Science Officer and co-founder.

"It is symbolic that the first chromosome transferred over the blockchain is Venter's as he was one of the key players in the completion of the first human genome ever sequenced as part of the human genome project," added Dr. Sines.  "The size of the diploid human genome is 1.5 Gigabytes, so it will require compression tools to significantly reduce DNA size; a must if one desires to use blockchain technologies. As a reference the average size of a transaction over the Ethereum blockchain is approximately less than 500 bytes."

When the human genome project was completed in 2003 after 13 years, the costs for sequencing a single genome summed up to US $3B, today full genome sequencing can be completed at the price of approximately US $450 and will soon reach less than US $100. The result is that millions of people will have their genome sequenced.

ABOUT DNAtix

DNAtix, the most cutting-edge genetics and blockchain company, is building the infrastructure for the world's genetic blockchain ecosystem. An ecosystem where researchers, hospitals, developers, clinicians and others will develop the next generation of decentralized genetics applications and health management solutions.  DNAtix is also delivering a direct-to-consumer platform that offers anonymous and encrypted genome sequencing and genetic services, including digitized DNA analysis, storage and transfer. The DNAtix genetics ecosystem is a place where consumers and the industry can meet to share genetic data in a more transparent, accessible, applicable and secured manner. DNAtix is developing the future ecosystem for genetics. A blockchain-based, cutting-edge new, innovative approach to DNA research. DNAtix is the first company to successfully transfer a genetic sequence over the Ethereum Blockchain, and now the first to transfer a complete chromosome. www.dnatix.com

  1. PLoS Biol. 2007 Sep 4;5(10):e254. The diploid genome sequence of an individual human.  Levy S1, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC.

Media Contact: 
Heidi Groshelle
Groshelle Communications
heidi@groshelle.com
415.307.1380




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DNAtix via Globenewswire

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye